Prevalence And Clinical Significance Of Oncogenic CD79B And MYD88 Mutations In Primary Testicular Diffuse Large B-Cell Lymphoma: A Retrospective Study In China.

Yan-Ping ChenLong-Feng KeJian-Ping LuJian-Chao WangWei-Feng ZhuFang-Fang ChenShao-Feng LinChun-Wei XuMei-Juan WuGang Chen

Published in: OncoTargets and therapy (2019)

Our results suggest that MYD88 and CD79B mutations are important drivers of immune-privileged site-associated DLBCL and highlight potential therapeutic targets for personalized treatment.

Keyphrases

diffuse large b cell lymphoma
epstein barr virus
toll like receptor
nk cells
transcription factor
germ cell
immune response
human health
replacement therapy
smoking cessation